Description
Sophoricoside is an isoflavone glycoside isolated from Sophora japonica and has anti-inflammatory, anti-cancer and immunosuppressive effects.
Product information
CAS Number: 152-95-4
Molecular Weight: 432.38
Formula: C21H20O10
Chemical Name: 5,7-dihydroxy-3-(4-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)-4H-chromen-4-one
Smiles: OC[C@H]1O[C@@H](OC2C=CC(=CC=2)C2=COC3=CC(O)=CC(O)=C3C2=O)[C@H](O)[C@@H](O)[C@@H]1O
InChiKey: ISQRJFLLIDGZEP-CMWLGVBASA-N
InChi: InChI=1S/C21H20O10/c22-7-15-18(26)19(27)20(28)21(31-15)30-11-3-1-9(2-4-11)12-8-29-14-6-10(23)5-13(24)16(14)17(12)25/h1-6,8,15,18-24,26-28H,7H2/t15-,18-,19+,20-,21-/m1/s1
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO : 41.67 mg/mL (96.37 mM; Need ultrasonic).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
Sophoricoside is an isoflavone glycoside isolated from Sophora japonica and has anti-inflammatory, anti-cancer and immunosuppressive effects. The results show that Sophoricoside (50 μM) significantly inhibits the PMACI-induced histamine release. The inhibition rate reaches up to 30.24%. The maximal rates of TNF-α, IL-8 and IL-6 inhibition by Sophoricoside (50 μM) are approximately 31.42%, 43.43% and 34.24%, respectively. The rates of the levels of Rel/p65 inhibition in nuclear by Sophoricoside (50 μM) is approximately 50.14%. Results show that the enhanced caspase-1 activity induced by PMACI is significantly reduced by Sophoricoside in a dose-dependent manner.
In Vivo:
When the Sophoricoside is orally administered 1 h before compound 48/80 injections, the scratching behaviors is reduced. The inhibition rate of Sophoricoside (2 mg/kg) is approximately 41.21%. Orally administered Sophoricoside inhibits the scratching behaviors by 47.31%. When mice are treated for 2 weeks with Sophoricoside, the atopic dermatitis is recovered to a significant extent.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.